RiverVest Venture Partners is a venture capital firm that focuses on building life science companies within the biopharma and medical device sectors. Their strategy involves identifying promising research and technology, then partnering with entrepreneurs to found and fund companies that develop novel therapies and medical devices to address significant unmet patient needs and deliver strong returns to investors.
62% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (50% of deals). Average disclosed round size is $84.1M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
$1.6B
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Sparrow Pharmaceuticals | Series B | $95M | Sep 2025 |
 Atalanta Therapeutics | Series B | $75M | Jan 2025 |
 Bluejay Therapeutics | Series C | $182M | May 2024 |
 Avalyn Pharma Inc. | Series C | $175M | Sep 2023 |
 Standard Bariatrics | Series B | $35M | Jun 2021 |
 Reneo Pharmaceuticals | Series A | $50M | May 2019 |
 VentureMed Group | Series B | $15M | Aug 2017 |
 Otonomy, Inc. | Series C | $45.9M | Sep 2013 |
Top Co-Investors
RA Capital Management2 shared
U.S. Venture Partners2 shared
Wellington Management2 shared
F-Prime Capital2 shared
Novo Holdings2 shared
Forbion1 shared
OrbiMed1 shared
NEA (New Enterprise Associates)1 shared
Pappas Capital1 shared
Norwest Venture Partners1 shared
SR One1 shared
Eventide Asset Management1 shared
Rock Springs Capital1 shared
T. Rowe Price Associates, Inc.1 shared
Surveyor Capital1 shared
Catalio Capital Management1 shared
Pivotal bioVenture Partners1 shared
Endeavour Vision1 shared
EQT Life Sciences1 shared
Last updated: 10 May 2026